Skip to Content
Merck
  • Phenotypic and transcriptional profiling in Entamoeba histolytica reveal costs to fitness and adaptive responses associated with metronidazole resistance.

Phenotypic and transcriptional profiling in Entamoeba histolytica reveal costs to fitness and adaptive responses associated with metronidazole resistance.

Frontiers in microbiology (2015-05-23)
Gil M Penuliar, Kumiko Nakada-Tsukui, Tomoyoshi Nozaki
ABSTRACT

Antimicrobial chemotherapy is critical in the fight against infectious diseases caused by Entamoeba histolytica. Among the drugs available for the treatment of amebiasis, metronidazole (MTZ) is considered the drug of choice. Recently, in vitro studies have described MTZ resistance and the potential mechanisms involved. Costs to fitness and adaptive responses associated with resistance, however, have not been investigated. In this study we generated an HM-1 derived strain resistant to 12 μM MTZ (MTZR). We examined its phenotypic and transcriptional profile to determine the consequences and mRNA level changes associated with MTZ resistance. Our results indicated increased cell size and granularity, and decreased rates in cell division, adhesion, phagocytosis, cytopathogenicity, and glucose consumption. Transcriptome analysis revealed 142 differentially expressed genes in MTZR. In contrast to other MTZ resistant parasites, MTZR did not down-regulate pyruvate:ferredoxin oxidoreductase, but showed increased expression of genes for a hypothetical protein (HP1) and several iron-sulfur flavoproteins, and downregulation of genes for leucine-rich proteins. Fisher's exact test showed 24 significantly enriched GO terms in MTZR, and a 3-way comparison of modulated genes in MTZR against those of MTZR cultured without MTZ and HM-1 cultured with MTZ, showed that 88 genes were specific to MTZR. Overall, our findings suggested that MTZ resistance is associated with specific transcriptional changes and decreased parasite virulence.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
E-64, protease inhibitor
Sigma-Aldrich
N,N′-Methylenebisacrylamide solution, suitable for electrophoresis, 2% in H2O
Sigma-Aldrich
L-Cysteine, from non-animal source, BioReagent, suitable for cell culture, ≥98%
Sigma-Aldrich
N,N′-Methylenebisacrylamide, suitable for electrophoresis (after filtration or allowing insolubles to settle)
SAFC
L-Cysteine
Sigma-Aldrich
L-Cysteine, BioUltra, ≥98.5% (RT)
Sigma-Aldrich
N,N′-Methylenebis(acrylamide), 99%
Sigma-Aldrich
L-Cysteine, 97%
Supelco
L-Cysteine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L-Cysteine, ≥97%, FG
Sigma-Aldrich
N,N′-Methylenebisacrylamide, powder, for molecular biology, suitable for electrophoresis, ≥99.5%
Sigma-Aldrich
L-Cysteine, produced by Wacker Chemie AG, Burghausen, Germany, ≥98.0%
Sigma-Aldrich
β-D-Allose, rare aldohexose sugar
SAFC
Sodium chloride solution, 5 M
Supelco
Sodium chloride, Pharmaceutical Secondary Standard; Certified Reference Material
Tinidazole, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Sodium chloride solution, 5 M
Supelco
Ornidazole, analytical standard
Sigma-Aldrich
Paromomycin sulfate salt, powder, BioReagent, suitable for cell culture, potency: ≥675 μg per mg
Sigma-Aldrich
Sodium chloride solution, 0.9% in water, BioXtra, suitable for cell culture
Sigma-Aldrich
Sodium chloride, BioXtra, ≥99.5% (AT)